Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-inWltrating lymphocytes as adjuvant therapy for stage III melanoma

Autor: Amir Khammari, Sylvain Bercegeay, Marie Christine Pandolfino, Jean-Michel Nguyen, Philippe Lemarre, Christelle Volteau, Francine Jotereau, Brigitte Dréno, Alain Cassidanius, Gaëlle Quéreux, Nathalie Labarrière, Anabelle Brocard
Přispěvatelé: Service de dermatologie [Nantes], Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes), PIMESP [CHU Nantes, Hôpital Saint-Jacques], Unité de Thérapie Cellulaire et Génique [CHU Nantes] (UTCG), Hôtel-Dieu-Centre hospitalier universitaire de Nantes (CHU Nantes), Recherches en cancérologie, Université de Nantes (UN)-IFR26-Institut National de la Santé et de la Recherche Médicale (INSERM), LABARRIERE, Nathalie
Jazyk: angličtina
Rok vydání: 2007
Předmět:
Adult
Oncology
Cancer Research
medicine.medical_specialty
Adoptive cell transfer
Adolescent
[SDV.IMM] Life Sciences [q-bio]/Immunology
medicine.medical_treatment
Immunology
[SDV.CAN]Life Sciences [q-bio]/Cancer
Disease-Free Survival
03 medical and health sciences
Lymphocytes
Tumor-Infiltrating
0302 clinical medicine
Adjuvants
Immunologic
[SDV.CAN] Life Sciences [q-bio]/Cancer
Recurrence
Internal medicine
medicine
Adjuvant therapy
Humans
Immunology and Allergy
Survivors
Stage (cooking)
Melanoma
Lymph node
Aged
Neoplasm Staging
Tumor-infiltrating lymphocytes
business.industry
Immunotherapy
[SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy
Middle Aged
medicine.disease
Adoptive Transfer
3. Good health
Surgery
medicine.anatomical_structure
030220 oncology & carcinogenesis
[SDV.IMM]Life Sciences [q-bio]/Immunology
Lymph
[SDV.IMM.IMM] Life Sciences [q-bio]/Immunology/Immunotherapy
business
Follow-Up Studies
030215 immunology
Zdroj: Cancer Immunology, Immunotherapy
Cancer Immunology, Immunotherapy, Springer Verlag, 2007, 56 (11), pp.1853-1860. ⟨10.1007/s00262-007-0340-1⟩
ISSN: 0340-7004
1432-0851
DOI: 10.1007/s00262-007-0340-1⟩
Popis: The first analysis of our clinical trial on interest of using tumor-infiltrating lymphocytes (TIL) as adjuvant therapy for stage III (regional lymph nodes) melanoma was published in 2002 [5]. The aim of this paper is to update clinical results of 7 years of follow-up after the last treated patient. In the trial conducted between December 1993 and January 1999, patients without any detectable metastases after lymph node excision were randomly assigned to receive either TIL plus interleukin-2 (IL-2) for 2 months, or IL-2 only. The duration of the relapse-free interval was the primary objective. Eighty-eight patients were enrolled in the study. Currently, the last analysis performed in June 2006, after a median follow-up of 114.8 months, did not show change of non-significant extension of the relapse-free interval or overall survival. However, this second analysis strengthens our first hypothesis about the relationship between number of invaded lymph nodes and TIL treatment effectiveness. In the group with only one invaded lymph node, the estimated relapse rate was significantly lower (P adjusted = 0.0219) and the overall survival was increased (P adjusted = 0.0125) in the TIL+IL-2 arm compared with the IL-2 only arm. No differences between the two arms, either with regard to the duration of disease-free survival (P adjusted = 0.38) or overall survival (P adjusted = 0.43), were noted in the group with more than one invaded lymph node, whatever the number of invaded lymph nodes. Treatment was compatible with normal daily activity. This study, with a very long follow up (median of almost 10 years), postulates for the first time relationship between TIL efficiency in stage III melanoma (AJCC) and number of invaded lymph nodes, indicating that tumor burden might be a crucial factor in the production of an effective in vitro expansion of T cells specific for autologous tumor antigen, a finding which could be of value in future vaccine development for the treatment of melanoma.
Databáze: OpenAIRE
Externí odkaz: